EPISODE · Apr 28, 2025 · 52 MIN
296. From Launch to 20K Users In Under 6 Months: How SheMed Turned Regulation Into Rapid Growth
from Cubicle to CEO · host Ellen Yin
What if making your product harder to access was the secret to increasing demand? That’s the counterintuitive strategy sisters Olivia and Chloe Ferro bet on to catapult their startup SheMed to over 20,000 sign-ups in just a few months. As the UK’s first female-focused GLP-1 program, SheMed entered a crowded weight-loss market—but instead of competing on convenience, they bet on credibility. By requiring mandatory blood tests before prescribing medication, they not only differentiated themselves but uncovered a staggering insight: 99% of applicants had undiagnosed health conditions. The payoff? A 3X surge in inbound leads, a 120% increase in patient sign-ups, and high-trust partnerships with major clinics—all fueled by a safety-first approach that turned medical rigor into a viral growth lever. If you’ve ever worried that implementing stricter client or customer qualifications might slow your sales, this case study is an excellent reminder that trust is your most powerful conversion strategy. Thank you to our sponsor! Get at least 15% off any annual Masterclass membership at https://masterclass.com/cubicletoCEO Connect with Chloe + Olivia: https://shemed.co.uk IG: @shemed_uk TikTok: @shemed_uk FB Group: SheMed UK TikTok: @shemed_uk LinkedIn: https://www.linkedin.com/in/chloe-ferro/ LinkedIn: https://www.linkedin.com/in/oliviaferro/ Iconic business leaders all have their own unique genius. Take this quick 10 question quiz to uncover your specific CEO style advantage: https://cubicletoceo.co/quiz If you enjoyed today's episode, please: Post a screenshot & key takeaway on your IG story and tag me @missellenyin & @cubicletoceo so we can repost you. Leave a positive review or rating at www.ratethispodcast.com/cubicletoceo Subscribe for new episodes every Monday. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
What if making your product harder to access was the secret to increasing demand? That’s the counterintuitive strategy sisters Olivia and Chloe Ferro bet on to catapult their startup SheMed to over 20,000 sign-ups in just a few months. As the UK’s first female-focused GLP-1 program, SheMed entered a crowded weight-loss market—but instead of competing on convenience, they bet on credibility. By requiring mandatory blood tests before prescribing medication, they not only differentiated themselves but uncovered a staggering insight: 99% of applicants had undiagnosed health conditions. The payoff? A 3X surge in inbound leads, a 120% increase in patient sign-ups, and high-trust partnerships with major clinics—all fueled by a safety-first approach that turned medical rigor into a viral growth lever. If you’ve ever worried that implementing stricter client or customer qualifications might slow your sales, this case study is an excellent reminder that trust is your most powerful conversion strategy. Thank you to our sponsor! Get at least 15% off any annual Masterclass membership at https://masterclass.com/cubicletoCEO Connect with Chloe + Olivia: https://shemed.co.uk IG: @shemed_uk TikTok: @shemed_uk FB Group: SheMed UK TikTok: @shemed_uk LinkedIn: https://www.linkedin.com/in/chloe-ferro/ LinkedIn: https://www.linkedin.com/in/oliviaferro/ Iconic business leaders all have their own unique genius. Take this quick 10 question quiz to uncover your specific CEO style advantage: https://cubicletoceo.co/quiz If you enjoyed today's episode, please: Post a screenshot & key takeaway on your IG story and tag me @missellenyin & @cubicletoceo so we can repost you. Leave a positive review or rating at www.ratethispodcast.com/cubicletoceo Subscribe for new episodes every Monday. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
296. From Launch to 20K Users In Under 6 Months: How SheMed Turned Regulation Into Rapid Growth
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m